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Commentary 
Context 
The management of acute venous thromboembolism (VTE) in patients with active 
cancer is challenging. In the landmark CLOT study1, low-molecular-weight heparin 
(LMWH) halved the incidence of recurrent VTE compared to vitamin K antagonists 
(VKAs) with similar rates of major bleeding. These observations were confirmed in 
additional smaller studies which together with the more stable pharmacokinetics of 
LMWH has led to the recommendation of LMWH over VKAs 2,3. Notwithstanding the 
favourable profile of LMWH, VKAs remain widely used world-wide. In this context, the 
results of the CATCH study were eagerly awaited.  
Methods 
The CATCH study was a two-arm parallel design randomized, open-label study with 
blinded central adjudication of study outcomes. 900 adult patients with active cancer and 
objectively documented VTE were randomized to 6 months of tinzaparin (175 IU/kg) 
once daily versus tinzaparin (175 IU/kg) once daily for 5 to 10 days followed by warfarin 
(target international normalized ratio 2.0 to 3.0). The primary efficacy outcome was a 
composite of recurrent symptomatic deep vein thrombosis (DVT), fatal or nonfatal 
pulmonary embolism (PE), and incidental VTE. Safety outcomes included major 
bleeding, clinically relevant non-major bleeding, and overall mortality. The results were 
reported as hazard ratio (HR) estimates with 95% confidence intervals (CIs). Overall, the 
trial design was strong with adequate concealment of allocation and statistical analyses 
according to the intent-to-treat principle. 
Findings 
The 6-month cumulative incidence of the primary outcome was 7.2% for tinzaparin vs 
10.5% for warfarin (HR 0.65, 95%CI 0.41 to 1.03). There was a difference in 
symptomatic DVT (HR 0.48, 95%CI 0.24 to 0.96) but not PE (HR 0.96, 95% CI 0.49 to 
1.88). The incidence of major bleeding was low and comparable between tinzaparin and 
warfarin (2.7% vs 2.4%; HR 0.89, 95%CI 0.40 to 1.99) while clinically relevant non-major 
bleeding was significantly reduced by tinzaparin (10.9% vs 15.3%; HR 0.58, 95% CI 0.40 
to 0.84). Overall mortality was similar (33.4% vs 30.6%; HR 1.08; 95%CI 0.85 to 1.36).  
Commentary 
Published in final edited form as: Evid Based Med. 2016 Apr;21(2):66. doi: 10.1136/ebmed-2015-110305
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
92
50
2 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
The CATCH study provides additional evidence on the efficacy and safety of LMWH for 
the treatment of acute VTE in cancer patients. A trend favouring full-dose tinzaparin over 
VKAs for recurrent VTE was observed, but the difference was smaller than anticipated, 
affecting the statistical power of CATCH. The rate of recurrent VTE in the tinzaparin was 
comparable to that observed with dalteparin in CLOT (7% vs 6%), whereas recurrent 
VTE in the warfarin group was lower than anticipated which could reflect critical 
differences between study populations. In CATCH, the prevalence of thrombotic risk 
factors (e.g. metastatic disease) was lower than in CLOT possibly resulting in a reduced 
risk of recurrent VTE. Another hypothesis for the lack of difference in efficacy could be a 
better control of VKAs therapy in CATCH, although this seems unlikely given the similar 
time in therapeutic range of VKAs. 
As previously observed with dalteparin, tinzaparin was not associated with 
reductions or increased risks in major bleeding or overall mortality. Of note, the 
incidence of major bleeding in CATCH was numerically lower compared to CLOT both in 
LMWH (2.7% vs. 6%) and VKAs (2.4% vs 4%), again suggesting differences in study 
populations. Tinzaparin lowered the rate of clinically relevant non-major bleeding 
compared to VKAs, but CATCH was not powered to detect differences in safety 
outcomes.  
Although we deem trials results valid, the “open design” puts the results at some 
risk of bias. The trialists attempted mitigating the potential for bias using blinded central 
adjudication of events, but we cannot exclude that the probability to detect an event 
through differential diagnostic work-up of, for example, clinically relevant non-major 
bleeding, was higher in the warfarin group due to lack of blinding of treating physicians. 
Adequate blinding may have attenuated observed differences even further. 
Implications for practice 
The CATCH study offers reassuring data on the safety of LMWH. Whether full dose 
regimens of LMWH other than tinzaparin have similar safety is unclear. The 
management of VTEs not included in the CATCH or CLOT studies (e.g. DVT of the 
upper extremities or splanchnic vein thrombosis) remains controversial. 
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